Targeted proteomics improves cardiovascular risk prediction in secondary prevention

Nick S. Nurmohamed(George Washington University), Erik S.G. Stroes(Amsterdam University Medical Centers), Michiel J. Bom(Amsterdam UMC Location Vrije Universiteit Amsterdam), João Pereira(Amsterdam University Medical Centers), Wolfgang Köenig(German Centre for Cardiovascular Research), Paul Knaapen(Amsterdam University Medical Centers), Renate M. Hoogeveen(Amsterdam University Medical Centers), Dominique P.V. de Kleijn(Utrecht University), Imo E. Hoefer(Utrecht University), Nathalie Timmerman(Utrecht University), Frank L.J. Visseren(University Medical Center Utrecht), Jeffrey Kroon(VIB-KU Leuven Center for Cancer Biology), Evgeni Levin(Horse Hospital), Jordan M Kraaijenhof(Amsterdam University Medical Centers), Alberico L. Catapano(University of Milan), Farahnaz Waissi(Utrecht University)
European Heart Journal
January 28, 2022
10.1093/eurheartj/ehac055
Cited by 133

Related Papers

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2021|6.1k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k